Baldus CD, Burmeister T, Martus P, Schwartz S, Gokbudget N, Bloomfield CD, Hoelzer D, Theil E, Hofmann WK. High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol 2006;24(29):4714-20.
Baldus CD, Thiede C, Soucek S, Bloomfield CD, Thiel E, Ehninger G. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J Clin Oncol 2006;24(5):790-797.
Becknell B, Hughes TL, Freud AG, Blaser BW, Yu J, Trotta R, Mao HC, Caligiuri de Jesus ML, Alghothani M, Benson DM Jr, Lehman A, Jarjoura D, Perrotti D, Bates MD, Caligiuri MA. The HIx homeobox transcription factor negatively regulates interferon-{gamma} production in monokine-activated natural killer cells. Blood 2007 Mar 15;109(6):2481-7. [Epub 2006 Nov 16]
Bekaii-Saab TS, Mortazavi A, Hicks LG, Zalupski M, Pelley RJ, Chan KK, Kraut EH. A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC). Invest New Drugs 2006;24(4):343-346.
Bekaii-Saab TS, Williams N, Plass C, Calero MV, Eng C. A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer 2006;6:278.
Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ, Kuzel TM, Angelotta C, McKoy JM, Bierman PJ, Kuter DJ, Trifilio SM, Devine SM, Tallman MS. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the research on adverse drug events and reports (RADAR) project. Br J Haematol 2006;135(5):642-650.
Blaser BW, Caligiuri MA. Autologous immune strategies to reduce the risk of leukemic relapse: consideration for IL-15. Best Pract Res Clin Haematol 2006;19(2):281-92.
Blaser BW, Schwind NR, Karol S, Chang D, Shin S, Roychowdhury S, Becknell B, Ferketich AK, Kusewitt DF, Blazer BR, Caligiuri MA. Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft versus host disease but not for graft-versus-tumor activity. Blood 2006;108(7):2463-9.
Bloomfield CD, Mrozek K, Caligiuri MA. Cancer and leukemia group B leukemia correlative science committee: major accomplishments and future directions. Clin Cancer Res 2006;12(11pt2):3564-3571.
Bloomston M, Bekaii-Saab TS, Kosuri K, Cowgill SM, Melvin WS, Ellison EC, Muscarella P 2nd. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection. Pancreas 2006;33(3):246-249.
Bloomston M, Muscarella P, Shah MH, Frankel WL, Al-Saif O, Martin EW, Ellison EC. Cytoreduction results in high periperative mortality and decreased survival in patients undergoing pancreatectomy for neuroendocrine tumors of the pancreas. J Gastrointest Surg 2006;10(10):1361-1370.
Blum W, Bolwell BJ, Phillips G, Farag SS, Lin TS, Avalos BR, Penza SL, Marcucci G, Byrd JC, Kalaycio ME, Sobecks RM, Pohlman B, Elder PJ, Copelan EA. High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation. Biol Blood Marrow Transplant 2006;12(1):61-67.
Breedlove HA, Smith AM, Burk RF, Hill KE, Shapiro CL. Serum selenium measurements in women with early stage breast cancer with and without chemotherapy induced ovarian failure. Breast Cancer Res Treat 2006;97(3):225-230.
Breza TS Jr, Zheng P, Porcu P, Magro CM. Cutaneous marginal zone B-cell-lymphoma in the setting of fluoxetine therapy: a hypothesis regarding pathogenesis based on the in vitro suppression of T-cell proliferative response. J Cutan Pathol 2006;33(7):522-528.
Byrd JC, Lin TS, Grever MR. Treatment of relapsed chronic lymphocytic leukemia: old and new therapies. Semin Oncol 2006;33(2):210-219.
Caligiuri MA. Recent advances in the treatment of transplant-related lymphoma. Clin Adv in Hematol Oncol 2006;4(1):32-33.
Chang S, Erdman JW Jr, Clinton SK, Vadiveloo M, Strom SS, Yamamura Y, Duphorne CM, Spitz MR, Amos CI, Contois JH, Cu X, Babainan RJ, Scardino PT, Hursting SD. Relationship between plasma carotenoids and prostate cancer. Nutr Cancer 2006;53(2):127-134.
Chen D, Song SH, Wientjes MG, Yeh TK, Zhao L, Villalona-Calero M, Otterson GA, Jensen R, Grever MR, Murgo AJ, Au JL. Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development. Pharm Res 2006;23(6):1265-1274.
Chen HC, Byrd JC, Muthusamy N. Differential role for cyclic AMP response element binding protein-1 in multiple stages of B cell development, differentiation and survival. J Immunol 2006;176(4):2208-2218.
Chen T, Hwang H, Rose ME, Nines RG, Stoner GD. Chemopreventive properties of black raspberries in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis: down-regulation of cyclooxygenase-2, inducible nitric oxide synthase and C-Jun. Cancer Res 2006;66(5):2853-2859.
Chen T, Rose ME, Hwang H, Nines RG, Stoner GD. Black raspberries inhibit N-nitrosomethylbenzylamine (NMBA)-induced angiogenesis in rat esophagus parallel to the suppression of COX-2 and iNOS. Carcinogenesis 2006;127(11):2301-2307.
Chiu SJ, Liu S, Perrotti D, Marcucci G, Lee RJ. Efficient delivery of a Bcl-2 specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targerted liposomes. J Controlled Release 2006;112(2):199-207.
Chiu SJ, Marcucci G, Lee RJ. Efficient delivery of an antisense oligodeoxyribonucleotide for formulated in folate receptor-targeted liposomes. Anticancer Res 2006;26(2):1049-1056.
Cohn DE, Frankel WL, Resnick KE, Zanagnolo VL, Copeland LJ, Hampel H, Kelbick N, Morrison CD, Fowler JM. Improved survival with an intact DNA mismatch repair system in endometrial cancer. Obstet Gynecol 2006;108(5):1208-15.
Dai Z, Liu S, Marcucci G, Sadee W. 5-Aza-2’-deoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting killer). Biochem Biophys Res Commun 2006;351(2):455-61.
De Angelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Drucker BJ, Heinrich MC. Phase I clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 2006 Dec 1;108(12):3674-81.
Dorrance AM, Liu S, Yuan W, Becknell B, Arnoczky KJ, Guimond M, Strout MP, Nakamura T, Yu L, Rush LJ, Weinstein M, Leone G, Wu L, Ferketich A, Whitman SP, Marcucci G, Caligiuri MA. MII partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J Clin Invest 2006;116(10):2707-26.
Duan W, Gao L, Wu X, Zhang Y, Otterson GA, Villalona-Calero MA. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells. Exp Cell Res 2006;312(17):3370-8.
Eniu A, Carlson RW, Aziz Z, Bines J, Hortobagyi GN, Bese NS, Love RR, Vikram B, Kurkure A, Anderson BO. Breast cancer in limited-resource countries: treatment and allocation of resources. Breast J 2006;1:38-53.
Farag SS, Archer KJ, Mrozek K, Ruppert AS, Carroll AJ, Vardiman JW, Pettenati MJ, Baer MR, Qumsiyeh MB, Koduru PR, Ning Y, Mayer RJ, Stone RM, Larson RA, Bloomfield CD. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006;108(1):63-73.
Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev 2006;20(3):123-127.
Farag SS, Caligiuri MA. Immunologic approaches to acute leukemia in the elderly. Semin Hematol 2006;43(2):118-125.
Freud AG, Caligiuri MA. Human natural killer cell development. Immunol Rev 2006;214(1):56-72.
Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, Ferketich AK, Caligiuri MA. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 2006;203(4):1033-1043.
Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee S, Yu J, Kaur B, Louis DN, Weissleder R, Caligiuri MA, Chiocca EA. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 2006;103(34):12873-12878.
Ganesan LP, Joshi T, Fang H, Kutala VK, Roda J, Trotta R, Lehman A, Kuppusamy P, Byrd JC, Carson WE, Caligiuri MA, Tridandapani S. Fc{gamma} R-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways. Blood 2006;108(2):718-725.
Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, Volinia S, Bhatt D, Alder H, Marcucci G, Calin GA, Liu CG, Bloomfield CD, Andreeff M, Croce CM. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci USA 2006;103(13):5078-5083.
Glaser R, Litsky MK, Padgett DA, Baiocchi RA, Yang EV, Yang EV, Chen M, Yeh PE, Green-Church K, Caligiuri MA, Williams MV. EBV-encoded dUTPase induces immune dysregulation: implications for the pathophysiology of EBV-associated disease. Virology 2006;346(1):205-218.
Guo Y, Wang S, Hoot DR, Clinton SK. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. J Nutr Biochem 2007 Jun;18(6):408-17. [Epub 2006 Dec 4]
Hallemeier CL, Girgis MD, Blum WG, Brown RA, Khoury HJ, Devine SM, Vij R, Lin HS, DiPersio JF, Adkins DR. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide. Biol Blood Marrow Transplant 2006;12(7):749-757.
Hecht SS, Huang C, Stoner GD, Li J, Kennedy PM, Sturla SJ, Carmella SG. Identification of cyanidin glycosides as constituents of freeze-dried black raspberries which inhibit anti-benzo[a]pyrene-7,8-diol-9,10-epoxide induced NF{kappa}B and AP-1 activity. Carcinogenesis 2006 Aug;27(8):1617-26.
Huang C, Li J, Song L, Zhang D, Tong Q, Ding M, Bowman L, Aziz R, Stoner GD. Black raspberry extracts inhibit benzo(a)pyrene diol-epoxide-induced activator protein 1 activation and VEGF transcription by targeting the phosphotidylinositol 3-kinase/Akt pathway. Cancer Res 2006;66(1):581-587.
Hu CJ, Chen SD, Yang DI, Lin TN, Chen CM, Huang TH, Hsu CY. Promotor region methylation and reduced expression of thrombospondin -1 after oxygen-glucose deprivation in murine cerebral endothelial cells. J Cereb Blood Flow Metab 2006;26(12):1519-26.
Johnson AJ, Lucas DM, Muthusamy N, Smith L, Edwards R, De Lay M, Croce CM, Grever MR, Byrd JC. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 2006;108(4):1334-1338.
Khan KD, Emmanouilides C, Benson DM Jr, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Procu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, Caligiuri MA. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin’s lymphoma. Clin Cancer Res 2006;12(23):7046-7053.
Kosuri K, Muscarella P, Bekaii-Saab TS. Updates and controversies in the treatment of pancreatic cancer. Clin Adv in Hematol Oncol 2006;4(1):47-54.
Kraut EH. The use of FEIBA for surgery in patients with haemophilia and inhibitors. Haemophilia 2006;5:20-5.
Kresty LA, Frankel WL, Hammond CD, Baird ME, Mele JM, Stoner GD, Fromkes JJ. Transitioning from preclinical to clinical chemopreventive assessments of lyophilized black raspberries: interim results show berries modulate markers of oxidative stress in Barrett’s esophagus patients. Nutr Cancer 2006;54(1):148-156.
Lara O, Tong X, Zborowski M, Farag S, Chalmers JJ. Comparison of two immunomagnetic separation technologies to deplete T cells from human blood samples. Biotechnol Bioeng 2006;94(1):66-80.
Li J, Zhu J, Melvin WS, Bekaii-Saab TS, Chen CS, Msucarella P. A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth. J Gastrointest Surg 2006;10(2):207-214.
Liao Z, Wang S, Wiegers BS, Clinton SK. Energy balance alters dunning R3327-H prostate tumor architecture, androgen receptor expression and nuclear morphometry in rats. Prostate 2006;66(9):945-953.
Lu H, Li J, Zhang D, Stoner GD, Huang C. Molecular mechanisms involved in chemoprevention of black raspberry extracts: from transcription factors to their target genes. Nutr Cancer 2006;54(1):69-78.
Liu TH, Raval A, Chen SS, Matkovic JJ, Byrd JC, Plass C. CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res 2006;66(2):653-658.
Liu Z, Marcucci G, Byrd JC, Grever M, Xiao J, Chan KK. Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2’-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun Mass Spectrom 2006;20(7):1117-1126.
Magro CM, Crowson AN, Morrison CD, Merati K, Porcu P, Wright ED. CD8+ lymphomatoid papulosis and its differential diagnosis. Am J Clin Pathol 2006;125(4):490-501.
Magro CM, Morrison CD, Heerema N, Porcu P, Sroa N, Deng AC. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism. J Am Acad Dermatol 2006;55(3):467-477.
Magro CM, Nash JW, Werling RW, Porcu P, Crowson N. Primary cutaneous CD30 + large cell B-cell lymphoma: a series of 10 cases. Appl Immunohistochem Molecul Morphol 2006;14(1):7-10.
Magro CM, Seilstad KH, Porcu P, Morrison CD. Primary CD20+CD10+CD8+T-cell lymphoma of the skin with IgH and TCR beta gene rearrangement. Am J Clin Pathol 2006;126(1):1-9.
Mikhalkevich B, Becknell B, Caligiuri MA, Bates MD, Harvey R, Zheng WP. Responsiveness of naïve CD4 T cells to polarizing cytokine determines the ratio of Th1 and Th2 cell differentiation. J Immunol 2006;176(3):1553-1560.
Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA, Guttridge D, Rhoades C, Shah M, Criswell T, Caligiuri MA, Villalona-Calero MA. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 2006;24(12):1852-1859.
Moore J, Seiter K, Kolitz J, Stock W, Giles F, Kalaycio M, Zenk D, Marcucci G. A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res 2006;30(7):777-783.
Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D, Kies M, Munden R, Busaidy N, Klein MJ, Sherman SI, Shah MH. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91(6):2201-2204.
Mrozek E, Ramaswamy B, Young D, Rhoades CA, Kendra K, Allen J, Moore T, Hauger M, Watson H, Merriman N, Nadella P, Villalona-Calero M, Shapiro CL. Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer. Clin Br Cancer 2006;7(2):141-145.
Mrozek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2006;169-177.
Notari M, Neviani P, Santhanam R, Bradley BW, Chang JS, Galietta A, Willis AE, Roy DC, Caligiuri MA, Marcucci G, Perrotti D. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood 2006;107(6):2507-2516.
Ozer E, Grecula J, Agrawal A, Rhoades CA, Young DC, Schuller DE. Long-term results of a multimodal intensification regimen for previously untreated advanced resectable squamous cell cancer of the oral cavity, oropharynx or hypopharynx. Laryngoscope 2006;116(4):607-612.
Palomero T, McKenna K, O-Neil J, Galinsky I, Stone R, Suzukawa K, Stiakaki E, Kalmanti M, Fox EA, Caligiuri MA, Aster JC, Look AT, Ferrando AA. Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias. Leukemia 2006;20(11):1963-6.
Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA, Vukosavljevic T, Perrotto D, Vardiman JW, Carroll AJ, Kolitz JE, Larson RA, Bloomfield CD. Adverse prognostic significance of KIT mutations in adult myeloid leukemia with inv (16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006;24(24):3904-3911.
Paskett ED, Schrag D, Kornblith A, Lamont EB, Weeks JC, Marshall JR, Shapiro C, Holland J. Cancer and leukemia group B cancer control and health outcomes committee: origins and accomplishments. Clin Cancer Res 2006;12(11):3601-3605.
Pereira MA, Yin D, Wu D, Chan KK, Miller DD, Dalton JT. In vivo metabolism and final disposition of a novel nonsteroidal androgen in rats and dogs. Drug Metab Dispos 2006;34(10):1713-21.
Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C. Phase II study of erlotinib in patients with advanced bilary cancer. J Clin Oncol 2006;24(19):3069-3074.
Pichiorri F, Trapasso F, Palumbo T, Aqeilan RI, Drusco A, Blaser BW, Iliopoulos D, Caligiuri MA, Huebner K, Croce CM. Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35. Clin Cancer Res 2006;12(11):3494-3501.
Porter PL, Barlow WE, Yeh IT, Lin MG, Yuan XP, Donato E, Sledge GW, Shapiro CL, Ingle JN, Haskell CM, Albain KS, Roberts JM, Livingston RB, Hayes DF. p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemo therapy. J Natl Cancer Inst 2006;98(23):1723-1731.
Radmacher MD, Marcucci G, Ruppert AS, Mrozek K, Whitman SP, Vardiman JW, Paschka P, Vukosavljevic T, Bldus C, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a cancer and leukemia group B study. Blood 2006;108(5):1677-1683.
Raval A, Byrd JC, Plass C. Epigenetics in chronic lymphocytic leukemia. Semin Oncol 2006;33(2):157-166.
Reen RK, Nines R, Stoner GD. Modulation of N-nitrosomethylbenzylamine metabolism by black raspberries in the esophagus and liver of Fischer 344 rats. Nutr Cancer 2006;54(1):47-57.
Ross P Jr, Grecula J, Bekaii-Saab T, Villalona-Calero M, Otterson G, Magro C. Incorporation of photodynamic therapy as an induction modality in non-small cell lung cancer. Laser Surg Med 2006;38(10):881-9.
Scott SK, Rabito FA, Price PD, Butler NN, Schwartzbaum JA, Jackson BM, Love RL, Harris RE. Comorbidity among the morbidly obese: a comparative study of 2002 US hospital discharges. Surg Obes Relat Dis 2006;2(2):105-111.
Shah MH, Binkley P, Chan KK, Xiao J, Arbogast D, Collamore M, Farra Y, Young D, Grever MR. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006;12(13):3997-4003.
Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med 2006;145(6):435-47.
Shepherd RM, Capoccia BJ, Devine SM, Dipersio J, Trinkaus KM, Ingram D, Link DC. Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD 3100. Blood 2006;08(12):3662-7.
Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson RA, Tallman MS, Bennett JM, Stirewalt DL, Meshinchi S, Willman CL, Ravindranath Y, Alonzo TA, Carroll AJ, Raimondi SC, Heerema NA. A retrospective study of 69 patients with t(6;9) (p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies. Leukemia 2006;20(7):1295-1297.
Smith LT, Lin M, Brena RM, Lang JC, Schuller DE, Otterson GA, Morrison CD, Smiraglia DJ, Plass C. Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. Proc Natl Acad Sci USA 2006;103(4):982-987.
Stock W, Yu D, Karrison T, Sher D, Stone RM, Larson RA, Bloomfield CD. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. Int J Oncol 2006;28(5):1099-1103.
Stoner GD, Chen T, Kresty LA, Aziz RM, Reinemann T, Nines R. Protection against esophageal cancer in rodents with lyophilized berries: potential mechanisms. Nutr Cancer 2006;54(1):33-46.
Tada Y, Brena RM, Hackanson B, Morrison C, Otterson GA, Plass C. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst 2006;98(6):396-406.
Tian Q, Giusti MM, Stoner GD, Schwartz SJ. Urinary excretion of black raspberry (Rubus occidentalis) anthocyanins and their metabolites. J Agric Food Chem 2006;54(4):1467-1472.
Tseng PH, Weng SC, Wang YC, Weng JR, Chen CS, Dunn SE, Pollak M, Chen CS, Brueggemeier RW, Shapiro CL. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived PDK-1 inhibitor. Mol Pharmacol 2006;70(5):1534-41.
Vandeusen JB, Shah MH, Becknell B, Blaser BW, Ferketich AK, Nuovo GJ, Ahmer BM, Durbin J, Caligiuri MA. STAT-1 mediated repression of monocyte interleukin-10 gene expression in vivo. Eur J Immunol 2006;36(3):623-630.
Wadehra N, Farag S, Bolwell B, Elder P, Penza S, Kalaycio M, Avalos B, Pohlman B, Marcucci M, Sobecks R, Lin T, Andresen S, Copelan E. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant 2006;12(12):1343-9.
Wetzler M, Brady MT, Tracy E, Li ZR, Donohue KA, O’Loughlin KL, Cheng Y, Mortazavi A, McDonald AA, Kunapuli P, Wallace PK, Baer MR, Cowell JK, Baumann H. Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. Clin Cancer Res 2006;12(22):6817-25.
Whittaker JK, Greene K, Shubert D, Blum R, Cheng K, Blum K, Reed N, Scott K, Roy R, Savas SA. Integration evidence-based practice in the child mental health agency: a template for clinical and organizational change. Am J Orthopsychiatry 2006;76(2):194-201.
Willis CR, Goodrich A, Park K, Waselenko JK, Lucas M, Reese A, Diehl LF, Grever MR, Byrd JC, Flinn IW. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin’s lymphoma. Ann Hematol 2006 May;85(5):301-7.
Yan PS, Venkataramu C, Ibrahim A, Liu JC, Shen RZ, Diaz NM, Centeno B, Weber F, Leu YW, Shapiro CL, Eng C, Yeatman TJ, Huang TH. Mapping geographical zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 2006;12(22):6626-6236.
Yang CC, Ku CY, Wei S, Shiau CW, Chen CS, Pinzone JJ, Ringel MD, Chen CS. Peroxisome proliferator-activated receptor {gamma}-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells. Mol Pharmacol 2006;69(5):1564-1570.
Yu J, Wei M, Becknell B, Trotta R, Liu S, Boyd Z, Jaung MS, Blaser BW, Sun J, Benson DM Jr, Mao H, Yokohama A, Bhatt D, Shen L, Davuluri R, Weinstein M, Marcucci G, Caligiuri MA. Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity 2006;24(5):575-590.